Skip to main content
Premium Trial:

Request an Annual Quote

Trapelo Health, Magellan Rx Team on Value-Based Precision Oncology

NEW YORK – Trapelo Health and the Magellan Rx Management pharmacy benefits management arm of Magellan Health on Thursday announced plans to bundle their technologies to build a platform to support value-based precision oncology care.

Trapelo, of Burlington, Massachusetts, makes a clinical decision support system that links healthcare providers, testing laboratories, and payors, giving them access to molecular testing information, ordering, and results interpretation in order to optimize utilization of molecular testing services and offer the most appropriate care to patients.

A company spokesperson said that the technology platform can manage a wide range of molecular tests including next-generation sequencing panels, single-gene tests, cytogenics, immunohistochemistry screening, and fluorescence in situ hybridization.

Magellan Rx Management, an Orlando, Florida-based division of Scottsdale, Arizona-based Magellan Health, provides oncology management services on behalf of payors to address issues including prior authorization, customized formulary management, personalized dosing, patient care management, and post-service claim edits.

"This [partnership] gives us a significant opportunity to advance our vision for a more collaborative approach in oncology that streamlines workflow and eases administrative burden for providers, labs, and payors while improving patient access and outcomes," Trapelo Health CEO Clynt Taylor said in a statement.

"We recognize that contemporary oncology care requires changes in the approach to oncology management," added Caroline Carney, CMO of Magellan Health and Magellan Rx Management. "This collaboration allows us to extend the value of the services we can provide to our health plan customers and strengthens our shared commitment to ensuring that every patient receives the opportunity for the best possible outcome."

Trapelo was acquired two weeks ago by cancer genetics testing laboratory NeoGenomics for $65 million.